Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$6.35 -3.4%	$6.54	$3.25 ▼ $56.80	$7.27M	0.64	23,878 shs	1,700 shs
BMRA Biomerica	$2.19 -0.2%	$2.12	$1.87 ▼ $4.60	$6.75M	0.28	20,722 shs	2,091 shs
SXTC China SXT Pharmaceuticals	$1.70 +2.3%	$1.93	$1.25 ▼ $1,046.99	$1.64M	1.96	227,636 shs	3,964 shs
TCRT Alaunos Therapeutics	$2.61 -2.2%	$3.02	$1.67 ▼ $6.20	$6.26M	-1.13	18,097 shs	174 shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+13.06%	+19.10%	+73.16%	-30.00%	-88.19%
BMRA Biomerica	-1.58%	-0.23%	+0.69%	-3.33%	-37.23%
SXTC China SXT Pharmaceuticals	-5.68%	-19.42%	-19.81%	-44.67%	-99.41%
TCRT Alaunos Therapeutics	+0.34%	+3.90%	-9.62%	+0.34%	-8.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$6.35 -3.4%	$6.54	$3.25 ▼ $56.80	$7.27M	0.64	23,878 shs	1,700 shs
BMRA Biomerica	$2.19 -0.2%	$2.12	$1.87 ▼ $4.60	$6.75M	0.28	20,722 shs	2,091 shs
SXTC China SXT Pharmaceuticals	$1.70 +2.3%	$1.93	$1.25 ▼ $1,046.99	$1.64M	1.96	227,636 shs	3,964 shs
TCRT Alaunos Therapeutics	$2.61 -2.2%	$3.02	$1.67 ▼ $6.20	$6.26M	-1.13	18,097 shs	174 shs

The 10 Best AI Stocks to Own in 2026

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+13.06%	+19.10%	+73.16%	-30.00%	-88.19%
BMRA Biomerica	-1.58%	-0.23%	+0.69%	-3.33%	-37.23%
SXTC China SXT Pharmaceuticals	-5.68%	-19.42%	-19.81%	-44.67%	-99.41%
TCRT Alaunos Therapeutics	+0.34%	+3.90%	-9.62%	+0.34%	-8.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.25	Hold	$89.00	1,300.91% Upside
BMRA Biomerica	1.00	Sell	$9.00	311.90% Upside
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, BMRA, AKTX, and TCRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2026	BMRA Biomerica	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
5/1/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
4/29/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/20/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
4/8/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/1/2026	AKTX Akari Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$27.00

(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
BMRA Biomerica	$4.33M	1.56	N/A	N/A	$1.61 per share	1.36
SXTC China SXT Pharmaceuticals	$1.54M	1.06	N/A	N/A	$3,187.45 per share	0.00
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-70.34%	-35.46%	N/A
BMRA Biomerica	-$4.97M	-$0.89	N/A	N/A	N/A	-96.49%	-98.14%	-70.42%	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$2.21	N/A	N/A	N/A	N/A	-172.65%	-123.32%	5/13/2026 (Estimated)

Latest SXTC, BMRA, AKTX, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/13/2026	Q3 2026	BMRA Biomerica	-$1.20	-$0.44	+$0.76	-$0.44	$3.63 million	$0.99 million
3/31/2026	Q4 2025	TCRT Alaunos Therapeutics	N/A	-$0.36	N/A	-$0.36	N/A	$0.00 million
3/30/2026	Q4 2025	AKTX Akari Therapeutics	-$0.03	-$2.68	-$2.65	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.44	0.44
BMRA Biomerica	N/A	2.64	1.59
SXTC China SXT Pharmaceuticals	N/A	4.37	4.24
TCRT Alaunos Therapeutics	N/A	2.45	2.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
BMRA Biomerica	22.28%
SXTC China SXT Pharmaceuticals	5.02%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	30.70%
BMRA Biomerica	18.00%
SXTC China SXT Pharmaceuticals	3.95%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.15 million	793,000	Not Optionable
BMRA Biomerica	60	3.09 million	2.53 million	No Data
SXTC China SXT Pharmaceuticals	90	963,000	925,000	Not Optionable
TCRT Alaunos Therapeutics	40	2.40 million	2.01 million	No Data

SXTC, BMRA, AKTX, and TCRT Headlines

Recent News About These Companies

Contrasting Alaunos Therapeutics (NASDAQ:TCRT) & Telomir Pharmaceuticals (NASDAQ:TELO)

May 6 at 4:17 AM | americanbankingnews.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, BMRA, AKTX, and TCRT Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$6.35 -0.23 (-3.45%)

As of 11:06 AM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Biomerica NASDAQ:BMRA

$2.18 -0.01 (-0.23%)

As of 11:12 AM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.70 +0.04 (+2.35%)

As of 11:11 AM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Alaunos Therapeutics NASDAQ:TCRT

$2.61 -0.06 (-2.25%)

As of 11:12 AM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, BMRA, AKTX, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, BMRA, AKTX, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, BMRA, AKTX, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, BMRA, AKTX, and TCRT Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Biomerica NASDAQ:BMRA

China SXT Pharmaceuticals NASDAQ:SXTC

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, BMRA, AKTX, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, BMRA, AKTX, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, BMRA, AKTX, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, BMRA, AKTX, and TCRT Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Biomerica NASDAQ:BMRA

China SXT Pharmaceuticals NASDAQ:SXTC

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools